RAAS inhibition therapy

Drug identity checked against registry records

Also recorded as Angiotensin II receptor blockers (ARBs); Angiotensin-converting enzyme (ACE) inhibitors

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseNCT05709444PTNPhase 2Completed2024-04-26Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.